# Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer

> **NCT07041437** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 48 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** SHR-A2102
- **DRUG:** Adebrelimab

## Key facts

- **NCT ID:** NCT07041437
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-01-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07041437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07041437, "Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07041437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*